Global Health Asia-Pacific Dec 2021-Jan 2022 Dec 2021 - Jan 2022 - Page 24

MEDICAL

LIQUID BIOPSY OF THE YEAR IN THE ASIA-PACIFIC 2021

GUARDANT HEALTH AMEA
Guardant Health Asia , Middle East and Africa ( AMEA ) has won the Liquid Biopsy of the Year Award at the Global Health Asia-Pacific Healthcare and Hospital Awards ceremony held on 8 December 2021 at the St . Regis Hotel in Singapore . The precision oncology company was recognised for advancing clinical adoption of the Guardant360 ® liquid biopsy test and adopting a patient-centric approach in its efforts to help guide treatment decisions for patients with advanced stage cancer . This awards programme recognises companies in the healthcare industry that have pushed boundaries of pleasing their customers at every stage and in every interaction .
“ We are pleased to receive this award from Global Health Asia-Pacific . This is a great tribute to our team of talented and passionate individuals who are impacting the lives of patients daily . In the coming years , we will be looking at tackling the whole continuum of cancer from early stage to advanced stage cancer and will be offering more of such products in the Guardant portfolio . We are committed to bending the cost and mortality curves of cancer in Asia , Middle East and Africa ,” said Simranjit Singh , Chief Executive Officer of Guardant Health AMEA .
Currently , the Guardant360 test is commercially available in 41 countries in AMEA . The company plans to expand their operations and make the test accessible to more oncologists in the region so that physicians can
Vivek Kapoor
receive comprehensive genomic profiling ( CGP ) information about their patient ’ s cancer and match them to appropriate therapies quickly .
Adopting a patient-centric approach is at the heart of Guardant ’ s workflow . At Guardant Health AMEA , this is done by ensuring a quick turnaround time for test results and offering mobile phlebotomy services to patients who find it difficult to travel to the hospital . With a simple blood draw from the patient , physicians can see the current genomic profile of the cancer in approximately seven days from sample receipt in the laboratory and recommend suitable treatment .
Guardant Health Japan , an affiliate of Guardant Health AMEA , has filed for regulatory approval of the Guardant360 test in February this year . The company is currently awaiting approval from Japan ’ s Ministry of Health , Labour and Welfare . Upon receiving this approval , Guardant Health AMEA aims to drive clinical adoption of the Guardant360 test in Japan .
Sharing his positive experiences of using the Guardant360 test in clinical practice , a leading medical oncologist from Bangalore , India , Dr Amit Rauthan said , “ The Guardant360 liquid biopsy test was effective in detecting actionable mutations in the solid tumors of my patients with advanced stage cancer and this helped me to make quick , reliable and effective treatment decisions .”
About Guardant Health AMEA Guardant Health AMEA is a joint venture between SoftBank and Guardant Health , Inc ., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests , vast data sets and advanced analytics . The Guardant Health oncology platform is designed to leverage its capabilities in technology , clinical development , regulatory and reimbursement to drive commercial adoption , improve patient clinical outcomes and lower healthcare costs . Visit us online at www . guardanthealthamea . com .
22 DECEMBER 2021 - JANUARY 2022 GlobalHealthAsiaPacific . com